X‑Chem Announces Achievement of Milestone In Orexia Collaboration
Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.
What a Year! X‑Chem 2021 in Review
The month of December is often a time to take stock and assess the accomplishments of the past year. As...
X‑Chem and Abilita Bio Announce a Joint Research Collaboration
(XChem), and Abilita Bio, Inc. (Abilita), both privately held biotechnology companies, announce today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets.
DEL Technology and Targeted Protein Degradation Discovery
Targeted protein degradation (TPD) is a rapidly growing field that aims to selectively eliminate disease-causing proteins.1,2 Proteolysis targeting chimeras (PTCs)...
A Track Record of Success
For those who didn’t notice, X-Chem underwent a major rebranding in mid-2021. We rolled out our new website, logo, color...